Bristol Myers Squibb (BMY) Short term Debt (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Short term Debt data on file, last reported at $2.3 billion in Q1 2026.

• Quarterly Short term Debt fell 35.06% year-over-year to $2.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 billion (down 35.06% YoY) and the FY2025 annual result came in at $2.3 billion, up 10.51% from the prior year.
• Short term Debt climbed to $2.3 billion in Q1 2026 per BMY's latest filing, from $2.3 billion in the prior quarter.
• Across five years, Short term Debt topped out at $7.5 billion in Q1 2022 and bottomed at $1.1 billion in Q3 2024.
• The 5-year median for Short term Debt is $3.5 billion (2024), against an average of $3.7 billion.
• The widest annual swing landed in 2022, when Short term Debt soared 323.3%; it then tumbled 80.28% in 2024.
• Tracing BMY's Short term Debt over 5 years: stood at $4.3 billion in 2022, then slipped by 26.85% to $3.1 billion in 2023, then tumbled by 34.4% to $2.0 billion in 2024, then increased by 10.51% to $2.3 billion in 2025, then gained by 2.08% to $2.3 billion in 2026.
• Per Business Quant, the three latest BMY Short term Debt figures stand at $2.3 billion (Q1 2026), $2.3 billion (Q4 2025), and $4.5 billion (Q3 2025).

Peer Comparison